No Data
shenzhen neptunus bioengineering (000078.SZ): The company's current medical device business is about tens of billions in scale.
On November 13, Glonghui reported that shenzhen neptunus bioengineering (000078.SZ) stated in its investor relations that the medical device distribution business has a higher gross profit level compared to the pharmaceutical distribution business and is relatively less affected by policies. Therefore, the medical device business is one of the key sectors for the company's development, with the current medical device business scale at about 10 billion. In the future, the company will expand the scale of its medical device agency and direct sales business, aiming to transform from a market agent to a company with foreign brand agency rights, introducing advanced technologies and high-quality products from foreign brands to further enhance the company's medical device business level and market competitiveness.
Neptune Biotech: Report for the third quarter of 2024
Neptune Biotech: 2024 Semi-Annual Report Summary
Neptune Biology: 2024 Semi-Annual Report
Shenzhen Neptunus Bioengineering (000078.SZ): the net income in the first half of the year was 45.4098 million yuan, a decrease of 48.21% year-on-year.
Shenzhen Neptunus Bioengineering (000078.SZ) announced its semi-annual report for 2024, with a total operating income of 16.631 billion yuan, a decrease of 16.65% year-on-year; net income attributable to shareholders of the listed company was 45.4098 million yuan, a decrease of 48.21% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 38.9017 million yuan, a decrease of 28.11% year-on-year; basic earnings per share was 0.0173 yuan.
Express News | Shenzhen Neptunus Bioengineering: Net income in the first half of 2024 decreased by 48.21% compared to the same period last year.
No Data
No Data